May 16th 2025
Integrating molecular testing into melanoma and SCC management enhances risk assessment and personalizes treatment, revolutionizing patient care in dermatology.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Cutaneous T-cell lymphoma: Poised for a new treatment paradigm
January 16th 2015Researchers are aiming to better understand the molecular signaling pathways and the immune microenvironment of cutaneous T-cell lymphoma. The use of targeted or mechanism-based therapies may lead to better-understood combinations, higher response rates and better survival.
Gigapixel camera has eye for melanoma
January 12th 2015Whole-body photographic camera developed out of U.S. military surveillance technology may have applications in dermatology. Dermatologists could one day use the camera to take whole-body images in high-risk patients; then, let a computer do the work of analyzing lesions that need attention.
FDA accelerates approval of melanoma drug
January 2nd 2015The Food and Drug Administration has granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma and for patients whose disease has progressed following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.
Experimental small molecule inhibitor shows promise as melanoma treatment option
November 21st 2014TAK-33 inhibited and regressed tumor growth in melanoma cell lines and patient-derived xenograft models. This “robust” success in the lab, according to a study published in Nov. 5, 2014 in Molecular Cancer Therapeutics, justifies continued clinical development as a potential therapy for melanoma patients.
Melanoma mortality rate 5 times higher in developed countries
October 28th 2014When researchers studied mortality from conditions with skin manifestations in developed versus developing countries, they found living in the developed world doesn’t always translate to lower death rates. Age-adjusted mortality for melanoma, for example, was about five times greater in the developed world than in developing countries.
Photoprotection crucial for all skin types
October 27th 2014Dermatologists need to be vigilant and more aware of the type and frequency of skin cancers that can occur in patients with darker Fitzpatrick Skin Types, an expert says. In addition to examining the “typical” sites where these tumors occur, dermatologists should also carefully inspect the oral mucosa as well as the palms and soles.
Childhood skin disease has unique challenges
September 17th 2014Therapeutics is one of the most significant challenges in pediatric dermatology. Children have been identified as “therapeutic orphans”, with few options that have FDA-approved pediatric indications. Access to new and novel treatments like biologics is especially limited. Supportive legislation, beginning with the Best Pharmaceuticals for Children Act (bpca.nichd.nih.gov), has marked the dawn of a new era.